source
- Epicrispr and Infinimmune secure $165 million in venture funding for epigenetic and antibody programsEpicrispr Biotechnologies announced a $90 million Series C round to push its epigenetic therapy program for facioscapulohumeral muscular dystrophy (FSHD). The lead candidate, EPI-321, is in a firs…
- Austria launches up to €100 million anchor investment for growth fund, aiming to channel half‑billion euros into biotechAustria's government announced a new national Startup & Scaleup Fund as part of the 2027/2028 budget, with an anchor investment of up to €100 million. The public money is designed to attract priva…